Gilead’s Trodelvy Shows Significant Progression-Free Survival Benefit in Aggressive Breast Cancer Trial
New trial results indicate Gilead Sciences’ Trodelvy significantly extends progression-free survival in advanced triple-negative breast cancer. The antibody-drug conjugate demonstrated a 38% risk reduction compared to standard chemotherapy when used as initial treatment.
Major Clinical Advance in Aggressive Breast Cancer Treatment
Gilead Sciences’ targeted therapy Trodelvy has reportedly demonstrated substantial benefits in treating an aggressive form of breast cancer, according to recent trial results presented at the European Society for Medical Oncology meeting in Berlin. Sources indicate the drug reduced the risk of disease progression by 38% when used as initial treatment for advanced triple-negative breast cancer (TNBC) compared to standard chemotherapy.
